Table 5.
Laboratory results and blood pressure measurements at baseline in diabetic cats treated with exenatide ER vs. placebo
| Variable | Exenatide ER | Placebo | Reference interval | P‐value | ||
|---|---|---|---|---|---|---|
| Median (range) | Mean (SD) | Median (range) | Mean (SD) | |||
| Haematocrit (%) | 37 (29–47) | 38 (4.9) | 34 (25–47) | 35 (6.7) | 33–45 | .268 |
| Leukocytes (103/μL) | 8.9 (3.2–20.5) | 9.3 (4.0) | 10.8 (4.8–22.1) | 11.6 (5.1) | 4.6–12.8 | .165 |
| Platelets (103/μL) | 340 (207–525) | 372 (108.5) | 347 (156–672) | 386 (143.2) | 180–680 | .923 |
| Glucose (mg/dL) | 329 (101–810) | 383 (174.0) | 428 (70–536) | 384 (135.6) | 72–162 | .543 |
| Fructosamine (μmol/L) | 620 (402–883) | 657 (162.4) | 582 (438–878) | 625 (134.0) | 202–340 | .604 |
| Cholesterol (mg/dL) | 256 (132–565) | 279 (113.6) | 267 (112–662) | 300 (150.0) | 101–263 | .000 |
| Triglycerides (mg/dL) | 79 (26–350) | 108 (96.8) | 70 (35–3478) | 578 (1104.2) | 26–114 | .537 |
| Total protein (g/dL) | 7.4 (6.4–11.4) | 7.7 (1.2) | 7.4 (6.3–8.3) | 7.3 (0.6) | 6.4–8.0 | .369 |
| Albumin (g/dL) | 3.6 (3.1–4.1) | 3.6 (0.3) | 3.5 (2.7–4.4) | 3.6 (0.4) | 3.0–4.0 | .760 |
| Urea (mg/dL) | 30.0 (17.6–52.1) | 30.3 (10.0) | 29.1 (21.6–37.2) | 28.9 (5.8) | 20.7–35.3 | .494 |
| Creatinine (mg/dL) | 1.1 (0.9–1.9) | 1.2 (0.3) | 1.2 (0.6–1.7) | 1.1 (0.3) | 1.1–1.8 | .460 |
| Sodium (mEq/L) | 157 (145–165) | 157 (5.5) | 158 (145–165) | 157 (4.9) | 158–165 | .848 |
| Chloride (mEq/L) | 118 (99–126) | 116 (7.4) | 116 (105–121) | 114 (5.1) | 121–131 | .280 |
| Potassium (mEq/L) | 4.7 (4.3–5.4) | 4.7 (0.3) | 4.8 (3.4–5.9) | 4.8 (0.8) | 3.8–5.4 | .690 |
| Phosphorus (mg/dL) | 4.5 (2.7–6.5) | 4.5 (0.9) | 4.2 (2.5–5.0) | 4.1 (0.7) | 2.8–5.6 | .130 |
| Calcium (mg/dL) | 10.3 (1.1–11.9) | 9.8 (2.5) | 10.4 (9.3–11.9) | 10.4 (0.7) | 9.6–11.2 | .810 |
| Bilirubin (mg/dL) | 0.09 (0.02–0.43) | 0.13 (0.1) | 0.08 (0.01–0.43) | 0.11 (0.1) | 0–0.2 | .747 |
| ALP (U/L) | 50 (30–112) | 54 (21.9) | 49 (32–92) | 54 (19.0) | 16–43 | .975 |
| ALAT (U/L) | 76 (34–424) | 122 (119.3 | 87 (33–379) | 110 (91.0) | 34–98 | .709 |
| ASAT (U/L) | 29 (19–215) | 45 (49.2) | 41 (17–133) | 48 (29.9) | 19–44 | .184 |
| DGGR‐Lipase (U/L) | 25 (11–92) | 29 (22.8) | 23 (13–48) | 25 (11.7) | 8–26 | .734 |
| Spec fPL (μg/L) | 2.2 (0.6–41.8) | 6.6 (11.0) | 3.0 (0.6–16.8) | 4.6 (4.4) | >5.3 | .878 |
| T4 (μg/L) | 1.5 (0.7–2.4) | 1.5 (0.5) | 1.4 (0.5–1.8) | 1.3 (0.5) | <3.5 | .434 |
| IGF‐1 (ng/mL)a | 372 (227–1163) | 524 (303.5) | 405 (167–1041) | 419 (223.6) | <1000 | .408 |
| UPCa | 0.22 (0.08–1.04) | 0.31 (0.3) | 0.2 (0.1–1.2) | 0.3 (0.3) | ≤0.40 | .913 |
| SAP (mm Hg)a | 144 (96–224) | 153 (42.2) | 145 (85–189) | 141 (30.1) | 80–160 | .573 |
SD, standard deviation; ALP, alkaline phosphatase; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; UPC, urine protein‐to‐creatinine ratio; SAP, systolic arterial pressure.
a
IGF‐1, UPC, and SAP were increased in 3, 3, and 4 cats of the exenatide ER group, respectively, and in 1, 4, and 3 cats of the placebo group, respectively.